For decades, the “innovation” in oncology has been synonymous with the drug pipeline—the discovery of a new kinase inhibitor or the refinement of a CAR-T cell therapy. However, a fundamental shift is occurring in how cancer care is delivered. The focus is expanding from what we treat with to how we manage the delivery of that care. At the center of this operational revolution is artificial intelligence (AI), which is moving beyond the realm of academic research and into the daily workflows of community clinics and hospital wards.
The integration of AI into oncology practice is no longer just about predicting a protein fold or identifying a mutation. It’s about solving the “administrative burden” that plagues modern medicine. From the automated documentation of patient encounters to the rapid synthesis of clinical guidelines, AI is being deployed to reclaim the time oncologists spend on screens, redirecting it back toward the patient. As these tools transition from experimental pilots to FDA-cleared medical devices, the delivery of care is becoming as personalized as the medicine itself.
This evolution is particularly critical in community oncology, where the vast majority of patients receive treatment but often lack the massive data-processing infrastructure of tertiary academic centers. By leveraging generative AI and machine learning, these practices are beginning to close the gap in decision support and operational efficiency, ensuring that a patient in a rural clinic has access to the same evidence-based insights as one at a premier cancer institute.
The Shift Toward Operational AI in Cancer Care
While AI’s role in early detection and drug discovery is well-documented, its application in the delivery of care focuses on the “friction points” of clinical practice. These include the exhaustive process of patient retrieval for clinical trials, the manual calculation of tumor response, and the constant need to cross-reference evolving clinical guidelines.
One of the most significant bottlenecks in oncology is the “Tumor Board”—the multidisciplinary meeting where specialists discuss complex cases. Traditionally, preparing for these meetings requires hours of manual data aggregation. New AI-driven smart patient retrieval systems
are now being advocated to identify similar prior cases with known outcomes, providing clinicians with immediate contextual evidence on disease trajectories and treatment responses according to Nature Reviews Cancer. This transforms the Tumor Board from a retrospective review into a prospective, data-driven strategy session.
Beyond the boardroom, the “administrative tax” on physicians is being addressed through ambient AI scribes. Tools such as DeepScribe and OncoSmart are being integrated into community practices to automate documentation and scheduling, reducing the burnout associated with electronic health record (EHR) maintenance as reported by AJMC. When a physician is no longer tethered to a keyboard during a consultation, the quality of the patient-provider relationship improves, which is a critical component of supportive care in oncology.
Precision Delivery: FDA-Cleared Tools and Real-Time Decision Support
The transition of AI from “experimental” to “clinical” is marked by regulatory clearance. The U.S. Food and Drug Administration (FDA) has recently cleared several AI-powered tools that standardize how oncologists assess treatment response and diagnose malignancies, removing the subjectivity that can lead to variability in care.
On March 25, 2026, InferVision announced that it received FDA clearance for InferCare RECIST
, a tool designed to bring AI-powered, standardized tumor assessment into routine oncology workflows per a company statement. By automating the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, the tool reduces the manual labor involved in measuring tumor shrinkage or growth across serial scans.
Other recent regulatory milestones include:
- Lung Cancer Screening: On February 11, 2026, the FDA issued a 510(k) clearance for eyonis® LCS, an AI/machine learning-powered software specifically for the detection and diagnosis of lung cancer according to ASCO AI.
- Prostate Prognosis: ArteraAI Prostate received FDA clearance as a Class II software algorithm device for analyzing digital images to provide cancer prognosis via an official FDA letter dated July 31, 2025.
- Mortality Stratification: The “Serial CTRS” deep learning model, developed by Onc.AI, was awarded FDA Breakthrough Device Designation in February 2025 for its ability to stratify non-small cell lung cancer (NSCLC) patients into high- or low-risk mortality categories according to Flatiron Health.
Democratizing Evidence: The AI Guidelines Revolution
One of the most daunting tasks for any oncologist is staying current with the sheer volume of new clinical data. The American Society of Clinical Oncology (ASCO) has addressed this by partnering with Google Cloud to create the ASCO Guidelines Assistant
. This interactive AI tool, built on Vertex AI and Gemini models, allows clinicians to navigate ASCO’s full library of clinical practice guidelines through a chat interface, providing evidence-based answers with clear citations according to ASCO.
The impact of this is the “democratization of expertise.” When a community oncologist can instantly verify a dosage or a treatment sequence against the gold standard of evidence, the risk of care variability decreases. This integration has expanded further; on March 17, 2026, it was announced that ASCO Guidelines would be integrated into DoxGPT, Doximity’s medical AI for clinicians per ASCO AI reporting.
However, the use of Large Language Models (LLMs) in precision oncology is not without risk. Recent reviews in the Journal of Hematology & Oncology emphasize that while generative AI can improve the quality of life by streamlining care, it requires rigorous governance to prevent “hallucinations” or the application of outdated data in critical decision-making processes published February 9, 2026.
Key Takeaways: AI’s Impact on Oncology Delivery
- From Academic to Community: AI tools are shifting from research centers to community practices, focusing on operational efficiency and decision support.
- Reducing Burnout: Ambient AI scribes and automated scheduling are reducing the administrative burden on oncologists.
- Standardized Assessment: FDA-cleared tools like InferCare RECIST are replacing manual tumor measurements with standardized, AI-driven assessments.
- Instant Evidence: Tools like the ASCO Guidelines Assistant provide real-time, cited access to clinical standards, reducing care variability.
The Path Forward: Governance and Human Oversight
As AI becomes an invisible layer of the oncology workflow, the industry is grappling with the “black box” problem—the difficulty of understanding how an AI reached a specific conclusion. The current consensus among medical leaders is that AI should function as “augmented intelligence” rather than “autonomous intelligence.”
Research published in Nature Cancer describes the development of autonomous AI agents leveraging GPT-4 for clinical decision-making, but emphasizes that these systems must be validated against multimodal precision oncology tools to ensure safety per Nature Cancer. The goal is a “human-in-the-loop” system where the AI handles the data synthesis and the physician handles the final clinical judgment and the emotional complexities of patient care.
The next critical checkpoint for the field will be the continued release of prospective evaluation data from large-scale AI integrations, such as the GEMINI study, which is evaluating AI integration into breast cancer screening across multiple workflow settings to determine the most effective way to deploy these tools in real-world environments according to Nature Cancer.
Do you believe AI will eventually replace the multidisciplinary tumor board, or will it always be a supporting tool? Share your thoughts in the comments below and share this article with your colleagues in the healthcare community.
Keep reading